18.04.2014 • NewsCarlyleCarlyle GroupDede Willams

Carlyle See Buyout Firms Focus on Emerging Markets

The global private equity industry will see more listed players in coming years, while focusing more on emerging markets, less on leverage and more on good management of their investments, a senior executive of the Carlyle Group said at an event in Rio de Janeiro, Brazil.

Buyout firms will have to focus on "value creation" or an active management to enhance returns on their investments, said Carlyle co-CEO David Rubenstein, He added that sovereign wealth funds will become the main source of money for the industry in coming years, an era he dubbed Private Equity 4.0.

One of the U.S. largest private-equity firms, Carlyle in January of this year acquired the diagnostics arm of U.S. pharmaceutical manufacturer Johnson & Johnson. In 2013 it bought the Performance Coatings business of U.S. chemical giant DuPont and in 2012 took a 13.5% stake in China's Meinian Onehealth Healthcare Group.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.